Astrana Health (ASTH) saw its stock plummet 12.05% in intraday trading on Friday, following the company's disappointing fourth-quarter 2024 results and lackluster guidance for 2025.
Despite an 88.4% year-over-year increase in revenue to $665.21 million, the healthcare provider missed Wall Street's expectations. The company reported an adjusted loss of $0.15 per share, falling short of analysts' estimates of $0.12 earnings per share.
Astrana Health's outlook for 2025 also failed to impress investors. The company forecasted revenue in the range of $2.5 billion to $2.7 billion and adjusted EBITDA of $170 million to $190 million, both lower than analysts' projections. The weaker guidance was attributed to headwinds from higher-than-expected Medicaid trends and costs associated with strategic investments in integration, automation, and AI.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。